Eurofins Archives - Medical Design Sourcing

Eurofins’ empowerDx launches at-home blood test in U.S.

Eurofins subsidiary empowerDx today launched its PFAS Exposure direct-to-consumer at-home test in the U.S.

Luxembourg-based Eurofins touts the per- and polyfluorinated alkyl substances (PFAS) test as the first direct-to-consumer, at-home test for determining the levels of PFAS in a person’s blood and measure 47 of the PFAS “forever chemical” compounds.

According to a news release, the CDC reports that exposure to such forever chemicals can cause adverse health effects including cancer, thyroid disease, immune suppression, elevated cholesterol, respiratory disease and decreased fertility.

Eurofins’ PFAS Exposure test, developed by Eurofins Environment Testing companies and their research partners, is a self-administered sampling kit that uses a simple finger prick rather than the blood draw process that has been required to date, the company said.

The kits offer an all-in-one solution with essentials for collection and trans…

Eurofins, Rite Aid launch OTC at-home COVID-19 test in U.S.

Eurofins, its empowerDX subsidiary and Rite Aid announced the launch of an over-the-counter, at-home COVID-19 PCR test kit.

Luxembourg-based Eurofins’ co-branded kits will be made available at all Rite Aid locations across 17 U.S. states, offering both symptomatic and asymptomatic users a way to test for COVID-19 at home, according to a news release.

Eurofins Viracor, an infectious disease testing laboratory, developed the test based on the company’s FDA emergency use authorized SARS-CoV-2 RT-PCR assay. Eurofins said its test is among the first COVID-19 tests to be authorized through an EUA for OTC use.

“We are excited to partner with Rite Aid and launch this at-home COVID-19 testing kit, making access to test kits widely available to people across the U.S through Rite Aid’s national network,” Eurofins CEO Gilles Martin said in the release. “Increasing population testing rates is an important step in fighting the pandemic, a…

Eurofins launches COVID-19 testing network to facilitate European travel

Eurofins announced today that it opened a network of about 500 COVID-19 testing centers across Europe to help facilitate summer travel.

Luxembourg-based Eurofins’ network covers major traveling hubs to provide testing accessibility in locations ranging from supermarkets to business parks and residential areas, too.

According to a news release, the company’s 500-center network is already developed, with plans to establish around 1,000 testing centers this month. The company also operates mobile testing centers to further increase availability and access, with those centers available to municipal authorities to reduce pressure on existing centers with added sampling capacity.

Each mobile collection center can process up to 200 PCR tests per day. Eurofins already launched the mobile service in Belgium, France and Germany.

Eurofins gains EUA for young children’s COVID test

Eurofins announced today that it received FDA emergency use authorization (EUA) for its at-home COVID-19 testing kit for children three years of age and older.

Luxembourg-based Eurofins’ Clinical Enterprise subsidiary became the first to receive EUA for an at-home nasal PCR test for young children with the empowerDX kit, according to a news release. In March, Eurofins launched the direct-to-consumer, FDA-authorized at-home COVID-19 test kit for consumers 18 years of age and older.

The test kit is available through Eurofins’ Clinical Enterprise/empowerDX subsidiary and can be ordered online for $99, while kits are also available for purchase on Amazon, at RiteAid and through Uber’s on-demand delivery service.

Eurofins’ kit includes step-by-step instructions for the user, a shallow nasal swab, a test tube and a pre-paid FedEx package for the simple return of samples, for which customers will receive results through a secure patient …

Eurofins launches 10-minute COVID-19 exposure testing device

Eurofins (Paris:ERF.PA) announced today that it launched its rapid point-of-care testing devices to identify past exposure to COVID-19.

The serology-based, finger-prick tests detect antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms, with results coming in just 10 minutes, according to a news release.

Get the full story at our sister site, MassDevice.

Eurofins launches 10-minute COVID-19 exposure testing device

Eurofins (Paris:ERF.PA) announced today that it launched its rapid point-of-care testing devices to identify past exposure to COVID-19.

The serology-based, finger-prick tests detect antibodies with a sensitivity of 94.5% from 19 days following the onset of symptoms, with results coming in just 10 minutes, according to a news release.

Eurofins’ CE-Marked INgezim dual-recognition immunochromatographic assays determine the presence of total antibodies (IgG, IgA and IgM) specific to SARS-CoV-2 in a single blood, serum and plasma sample by using nucleoprotein as an antigen to detect the antibodies.

Kits for the assay include all materials needed to perform the finger-prick test, with analysis capable of being performed outside a laboratory, although the tests are intended for use by healthcare professionals and not for self-diagnosis.

According to the release, more than 400 sera samples were observed to validate the assays, as no cross-reactivity…